AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31513877 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitional stepping under unstable conditions (VOL + US)
Number of subjects: 51
Study 31513877 — intervention group
Group type: EXPERIMENTAL
Intervention: Volitional stepping (VOL)
Number of subjects: 51
Study 28271430 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPIRE-Group
Number of subjects: 332
Study 28271430 — intervention group
Group type: EXPERIMENTAL
Intervention: ASPIRE-Phone
Number of subjects: 332
Study 28271430 — intervention group
Group type: EXPERIMENTAL
Intervention: MOVE!
Number of subjects: 332
Study 26169621 — intervention group
Group type: EXPERIMENTAL
Intervention: CAU + BREATH
Number of subjects: 150
Study 26169621 — intervention group
Group type: COMPARATOR
Intervention: CAU alone
Number of subjects: 150
Study 23460682 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpartum anxiety screening and care model intervention
Number of subjects: 1123
Study 23460682 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1123
Study 22480102 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin with supportive management
Number of subjects: 100
Study 22480102 — intervention group
Group type: COMPARATOR
Intervention: Supportive therapy only (Control)
Number of subjects: 100
Study 20112821 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga training (Group A)
Number of subjects: 120
Study 20112821 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 120
Study 16736390 — intervention group
Group type: EXPERIMENTAL
Intervention: Family intervention followed by a support group
Number of subjects: 0
Study 16736390 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 16121901 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored newsletters and specialized cleaning
Number of subjects: 0
Study 16121901 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored newsletters
Number of subjects: 0
Study 16121901 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study 11291803 — intervention group
Group type: EXPERIMENTAL
Intervention: AV junction ablation and VVIR pacemaker
Number of subjects: 50
Study 9272427 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone 600 mg/day
Number of subjects: 0
Study 9272427 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous HRT (25 or 50 micrograms/day of transdermal 17 beta‐estradiol plus medrogestone 5 mg/day for 12 days/month)
Number of subjects: 0
Study 9272427 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipriflavone 600 mg/day plus 17 beta‐estradiol 25 micrograms/day plus medrogestone 5 mg/day for 12 days/month
Number of subjects: 0
Study 9272427 — intervention group
Group type: COMPARATOR
Intervention: Calcium 500 mg/day (control group)
Number of subjects: 0
Study 9272427 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose HRT (not specified)
Number of subjects: 0
Study 30141290 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with local exercise (active acupuncture group)
Number of subjects: 60
Study 30141290 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture (control group)
Number of subjects: 60
Study 27513651 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline systolic blood pressure (SBP)
Number of subjects: 21727
Study 27513651 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline low-density lipoprotein cholesterol (LDL-C)
Number of subjects: 21727
Study 27513651 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline SBP and LDL-C in the diabetic subgroup
Number of subjects: 21727
Study 25395844 — intervention group
Group type: EXPERIMENTAL
Intervention: BodyBalance training (2 sessions per week for 12 weeks)
Number of subjects: 28
Study 25395844 — intervention group
Group type: COMPARATOR
Intervention: Normal activities (control group)
Number of subjects: 28
Study 23844570 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote patient reporting of health status parameters and linked health behavior change feedback (n=24)
Number of subjects: 48
Study 23844570 — intervention group
Group type: COMPARATOR
Intervention: Standard of care including diabetes education and healthcare provider counseling (n=24)
Number of subjects: 48
Study 19524315 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic prophylactic gastrostomy
Number of subjects: 0
Study 19524315 — intervention group
Group type: COMPARATOR
Intervention: No systematic gastrostomy
Number of subjects: 0
Study 18543683 — intervention group
Group type: EXPERIMENTAL
Intervention: travoprost 0.004%
Number of subjects: 26
Study 18543683 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost 0.005%
Number of subjects: 26
Study 15473114 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid foot orthoses
Number of subjects: 50
Study 15473114 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study 11810122 — intervention group
Group type: EXPERIMENTAL
Intervention: Normobaric oxygen therapy
Number of subjects: 307
Study 11810122 — intervention group
Group type: COMPARATOR
Intervention: Combination of normobaric plus hyperbaric oxygen therapy
Number of subjects: 307
Study 11810122 — intervention group
Group type: EXPERIMENTAL
Intervention: Dizziness before admission
Number of subjects: 307
Study 11810122 — intervention group
Group type: EXPERIMENTAL
Intervention: Headaches upon hospital admission
Number of subjects: 307
Study 10073211 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted community-wide interventions to increase mammography screening rates.
Number of subjects: 0
Study 10073211 — intervention group
Group type: COMPARATOR
Intervention: Control community (no intervention).
Number of subjects: 0
Study 7979936 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrist splinting at 20 degrees extension
Number of subjects: 0
Study 7979936 — intervention group
Group type: COMPARATOR
Intervention: Wrist splinting at neutral angle
Number of subjects: 0
Study 2498571 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-(3-Methylcinnamylhydrazono)-Propionate (MCHP)
Number of subjects: 0
Study 2498571 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 1207435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1207435 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (4 mg/kg)
Number of subjects: 0
Study 1207435 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (7 mg/kg)
Number of subjects: 0
Study 1207435 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (10 mg/kg)
Number of subjects: 0
Study 30661687 — intervention group
Group type: EXPERIMENTAL
Intervention: 25(OH)VitD 2.000 IU/day p.o. (Suppl group)
Number of subjects: 50
Study 30661687 — intervention group
Group type: COMPARATOR
Intervention: No supplementation (No-Suppl group)
Number of subjects: 50
Study 29131090 — intervention group
Group type: EXPERIMENTAL
Intervention: Online self-help program (Deprexis)
Number of subjects: 229
Study 29131090 — intervention group
Group type: COMPARATOR
Intervention: Active control group (weekly online information on depression)
Number of subjects: 229
Study 24821459 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved fixation method using an indwelling needle and membrane cover
Number of subjects: 65
Study 24821459 — intervention group
Group type: COMPARATOR
Intervention: Traditional fixation method using a haemostat, elastic band and abdominal bandage
Number of subjects: 65
Study 23965772 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent sex with a man
Number of subjects: 2146
Study 23965772 — intervention group
Group type: EXPERIMENTAL
Intervention: Reported bisexual behavior
Number of subjects: 2146
Study 23965772 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of study visits with recent sex with men
Number of subjects: 2146
Study 21812890 — intervention group
Group type: EXPERIMENTAL
Intervention: Premeal insulin glulisine
Number of subjects: 322
Study 21812890 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmeal insulin glulisine
Number of subjects: 322
Study 19345987 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic radical hysterectomy
Number of subjects: 63
Study 19345987 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic radical hysterectomy
Number of subjects: 63
Study 19345987 — intervention group
Group type: COMPARATOR
Intervention: Radical abdominal hysterectomy
Number of subjects: 63
Study 17468795 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional physiotherapy with home training
Number of subjects: 214
Study 17468795 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional physiotherapy without home training
Number of subjects: 214
Study 17468795 — intervention group
Group type: EXPERIMENTAL
Intervention: New sling exercise therapy with home training
Number of subjects: 214
Study 17468795 — intervention group
Group type: EXPERIMENTAL
Intervention: New sling exercise therapy without home training
Number of subjects: 214
Study 15464258 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioartificial liver (BAL)
Number of subjects: 171
Study 15464258 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 171
Study 11587278 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐peroxidase diet group
Number of subjects: 1203
Study 11587278 — intervention group
Group type: COMPARATOR
Intervention: No diet group
Number of subjects: 1203
Study 9439546 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 0
Study 9439546 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzbromarone
Number of subjects: 0
Study 8178325 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm (Group A)
Number of subjects: 66
Study 8178325 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Group S)
Number of subjects: 66
Study 3067735 — intervention group
Group type: EXPERIMENTAL
Intervention: Subunit vaccine
Number of subjects: 102
Study 3067735 — intervention group
Group type: COMPARATOR
Intervention: Whole virus vaccine
Number of subjects: 102
Study 31744798 — intervention group
Group type: EXPERIMENTAL
Intervention: LOADING group (3 monthly injections followed by as needed)
Number of subjects: 82
Study 31744798 — intervention group
Group type: COMPARATOR
Intervention: PRN group (treated as needed from the beginning)
Number of subjects: 82
Study 31744798 — intervention group
Group type: EXPERIMENTAL
Intervention: LOADING group
Number of subjects: 82
Study 31744798 — intervention group
Group type: COMPARATOR
Intervention: PRN group
Number of subjects: 82
Study 31744798 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study 31061013 — intervention group
Group type: EXPERIMENTAL
Intervention: KIDNEYTEXT intervention group receiving three text messages per week for 6 months providing customised dietary information and advice based on renal dietary guidelines and general healthy eating dietary guidelines.
Number of subjects: 130
Study 31061013 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 130
Study 27784687 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice
Number of subjects: 10
Study 27784687 — intervention group
Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (placebo)
Number of subjects: 10
Study 26248150 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiral flow-generating tube (protocol A)
Number of subjects: 100
Study 26248150 — intervention group
Group type: COMPARATOR
Intervention: Conventional connecting tube (protocol B)
Number of subjects: 100
Study 23327349 — intervention group
Group type: EXPERIMENTAL
Intervention: Low plasma citrulline levels
Number of subjects: 135
Study 23327349 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest citrulline quartile
Number of subjects: 135
Study 23327349 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrulline levels
Number of subjects: 135
Study 21277674 — intervention group
Group type: EXPERIMENTAL
Intervention: EE 20 μg/drsp 3mg in a 24/4 regimen for 7 or 13 cycles
Number of subjects: 2386
Study 19627679 — intervention group
Group type: EXPERIMENTAL
Intervention: Strength training intervention for 12 weeks
Number of subjects: 3
Study 17434511 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH-a (tryptorelin or leuprorelin, 3.75 mg every 28 days)
Number of subjects: 222
Study 17434511 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous estroprogestin (ethynilestradiol, 0.03 mg plus gestoden, 0.75 mg)
Number of subjects: 222
Study 17434511 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary therapy (vitamins, minerals salts, lactic ferments, fish oil)
Number of subjects: 222
Study 17434511 — intervention group
Group type: COMPARATOR
Intervention: Surgery plus placebo
Number of subjects: 222
Study 17434511 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative medical and dietary therapy
Number of subjects: 222
Study 15366275 — intervention group
Group type: EXPERIMENTAL
Intervention: Realism framework in evidence based medicine
Number of subjects: 0
Study 15366275 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence based medicine adopting realism
Number of subjects: 0
Study 11820707 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate 5 mg daily for 3 months
Number of subjects: 66
Study 11820707 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 9552063 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD30 levels measured at diagnosis and after induction polychemotherapy
Number of subjects: 70
Study 9552063 — intervention group
Group type: COMPARATOR
Intervention: sCD30 levels
Number of subjects: 70
Study 8151464 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol (17.1 ± 5.9 ng/kg per day)
Number of subjects: 94
Study 8151464 — intervention group
Group type: COMPARATOR
Intervention: Dihydrotachysterol (13.8 ± 3.3 micrograms/kg per day)
Number of subjects: 94
Study 2453990 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUE Test (TT)
Number of subjects: 292
Study 2453990 — intervention group
Group type: COMPARATOR
Intervention: Finn Chamber (FC)
Number of subjects: 292
Study 2453990 — intervention group
Group type: EXPERIMENTAL
Intervention: TRUE Test (TT) and Finn Chamber (FC)
Number of subjects: 292
Study 30924372 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonopioid medications
Number of subjects: 68
Study 30924372 — intervention group
Group type: COMPARATOR
Intervention: Opioid medications
Number of subjects: 68
Study 31543973 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 64
Study 31543973 — intervention group
Group type: COMPARATOR
Intervention: Insulin detemir (IDet)
Number of subjects: 64
Study 30184007 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (2mA for five 20-min sessions)
Number of subjects: 14
Study 30184007 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 14
Study 26523398 — intervention group
Group type: EXPERIMENTAL
Intervention: Instructional self-statement
Number of subjects: 96
Study 26523398 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational auditory feedback
Number of subjects: 96
Study 26523398 — intervention group
Group type: COMPARATOR
Intervention: Vicarious experiences
Number of subjects: 96
Study 26523398 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal persuasion
Number of subjects: 96
Study 25183741 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft surgery
Number of subjects: 188
Study 25183741 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention
Number of subjects: 188
Study 25183741 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 188
Study 22094303 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised patient care as an adjunct to standard care
Number of subjects: 127
Study 22094303 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 127
Study 20846586 — intervention group
Group type: EXPERIMENTAL
Intervention: Tigecycline
Number of subjects: 945
Study 20846586 — intervention group
Group type: COMPARATOR
Intervention: Imipenem/Cilastatin
Number of subjects: 945
Study 17591563 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP chemotherapy (Cyclophosphamide, doxorubicin, vincristine, and prednisone)
Number of subjects: 0
Study 17591563 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOP chemotherapy with rituximab
Number of subjects: 0
Study 17591563 — intervention group
Group type: COMPARATOR
Intervention: Dose-dense and/or dose-intense regimens
Number of subjects: 0
Study 17591563 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 0
Study 15867495 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-focused adherence intervention
Number of subjects: 215
Study 15867495 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 215
Study 11937621 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-exchange program (NEP); n = 296; median follow-up = 261 days
Number of subjects: 600
Study 11937621 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle-exchange program (NEP) users; n = 65; median follow-up = 199 days
Number of subjects: 600
Study 11937621 — intervention group
Group type: EXPERIMENTAL
Intervention: NEP usage predictors
Number of subjects: 600
Study 9861598 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 80% VO2max
Number of subjects: 12
Study 9861598 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling at 60% VO2max
Number of subjects: 12
Study 9861598 — intervention group
Group type: EXPERIMENTAL
Intervention: Resting BE
Number of subjects: 12
Study 7829792 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid
Number of subjects: 14916
Study 7829792 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid
Number of subjects: 14916
Study 7829792 — intervention group
Group type: COMPARATOR
Intervention: Fish oil consumption
Number of subjects: 14916
Study 2396473 — intervention group
Group type: EXPERIMENTAL
Intervention: Parotin (oral adjuvant)
Number of subjects: 0
Study 2396473 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (oral adjuvant)
Number of subjects: 0
Study 2396473 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine + Lithium (oral adjuvant)
Number of subjects: 0
Study 2396473 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine + Parotin (oral adjuvant)
Number of subjects: 0
Study 2396473 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine + Parotin + Lithium (oral adjuvant)
Number of subjects: 0
Study 2396473 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine + Lithium + Parotin (oral adjuvants)
Number of subjects: 0
Study 2396473 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvanted vaccines (control)
Number of subjects: 0
Study 2396473 — intervention group
Group type: COMPARATOR
Intervention: Non-adjuvant control group
Number of subjects: 0
Study 314716 — intervention group
Group type: EXPERIMENTAL
Intervention: Sufentanil (SF)
Number of subjects: 54
Study 314716 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (F)
Number of subjects: 54
Study 314716 — intervention group
Group type: EXPERIMENTAL
Intervention: Both analgesics
Number of subjects: 54
Study 31951627 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium rejection
Number of subjects: 121
Study 31951627 — intervention group
Group type: COMPARATOR
Intervention: Included
Number of subjects: 121
Study 31951627 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe rejection
Number of subjects: 121
Study 31951627 — intervention group
Group type: EXPERIMENTAL
Intervention: High rejection sensitivity
Number of subjects: 121
Study 31722374 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-hyperglycemic medications
Number of subjects: 0
Study 31722374 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian Randomization
Number of subjects: 0
Study 31722374 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical implications for patients with obesity, diabetes, and cancer
Number of subjects: 0
Study 28846769 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Care (CC)
Number of subjects: 377
Study 28846769 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 377
Study 25676203 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracoscopic esophagectomy
Number of subjects: 379
Study 23141816 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin (30 μg/kg per day)
Number of subjects: 1161
Study 23141816 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1161
Study 23141816 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin
Number of subjects: 1161
Study 21787070 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral activation-enhanced orientation classes (n = 37)
Number of subjects: 71
Study 21787070 — intervention group
Group type: COMPARATOR
Intervention: Control orientation as usual classes (n = 34)
Number of subjects: 71
Study 21787070 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 71
Study 19217991 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose warfarin 1 mg per day
Number of subjects: 1590
Study 19217991 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-adjusted warfarin
Number of subjects: 1590
Study 19217991 — intervention group
Group type: COMPARATOR
Intervention: No warfarin
Number of subjects: 1590
Study 19217991 — intervention group
Group type: COMPARATOR
Intervention: Warfarin (combined fixed-dose and dose-adjusted)
Number of subjects: 1590
Study 17141179 — intervention group
Group type: EXPERIMENTAL
Intervention: Training to resolve descriptions of ambiguous events positively
Number of subjects: 0
Study 17141179 — intervention group
Group type: COMPARATOR
Intervention: Test-retest control condition
Number of subjects: 0
Study 15219265 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol (12 microg bid)
Number of subjects: 35
Study 15219265 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol (50 microg bid)
Number of subjects: 35
Study 15219265 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol
Number of subjects: 35
Study 15219265 — intervention group
Group type: COMPARATOR
Intervention: Salmeterol
Number of subjects: 35
Study 15219265 — intervention group
Group type: EXPERIMENTAL
Intervention: Formoterol and Salmeterol
Number of subjects: 35
Study 11711322 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Number of subjects: 58
Study 11711322 — intervention group
Group type: COMPARATOR
Intervention: Buffered regular human insulin
Number of subjects: 58